The Insurance Industry's Death Machine

The first step of the playbook is simple: say no. Not because the claim is invalid. Because most patients won't fight it.

Denial rates across major US insurers run from 15% to 32%. UnitedHealthcare — the largest private health insurer in the country — denied approximately one in three in-network claims during the final years of CEO Brian Thompson's tenure. The industry average was half that. The gap is not actuarial. It is strategic.

The economic logic is contained in a single statistic from the Kaiser Family Foundation: fewer than 0.2% of patients ever appeal a denied claim. The health insurance business model depends on this. Every denied-and-not-appealed dollar is pure margin — the premium was collected, the care was not paid for. The math does not require malice to generate casualties. It requires only indifference and scale.

Denial is mechanized through two main instruments:

Algorithmic denial systems. UnitedHealthcare's nH Predict algorithm, purchased via the $2.5 billion naviHealth acquisition in 2020, automatically denied post-acute care coverage to elderly Medicare Advantage patients whose hospital stays exceeded the algorithm's predicted discharge dates — regardless of what their treating physicians recommended. The Senate Permanent Subcommittee on Investigations obtained 280,000+ pages of internal documents showing employees were directed to "follow the algorithms and basically not use your clinical judgment." The algorithm's predicted discharge date rose from 8.7% denial rate in 2019 to 22.7% denial rate by 2022. The denial rate on appealed decisions: 80.7% reversed. The machine was wrong, at scale, by design.

Cigna's PXDX automated system — documented by ProPublica in March 2023 — denied approximately 300,000 claims in a two-month window reviewed by physicians for an average of 1.2 seconds each. "Deny and defend" was the institutional instruction, per internal communications obtained by ProPublica. The medical directors reviewing these claims described them as essentially rubber-stamped: the system generates the denial, the physician confirms it in under two seconds, the patient receives a form letter.

Ambiguous exclusion clauses. "Medical necessity" is defined subjectively by insurer-employed reviewers. The phrase appears in virtually every health insurance contract in the United States and means, in practice, whatever the insurer decides it means for each claim. Courts have generally deferred to insurer determinations of medical necessity — a deference that functions as structural permission to deny.

When initial denial isn't clean enough — when the claim is clearly valid, when a physician is persistent, when a patient has resources — the next instrument is time. Process the claim slowly. Request documents in increments. Generate administrative drag at every stage. The clock runs against the patient, always.

Prior authorization is the primary delay mechanism. Insurers require physicians to obtain advance approval for treatments, medications, and procedures before they are covered. The stated rationale is cost control and appropriateness review. The operational effect: weeks of administrative processing between a physician's recommendation and coverage approval — during which patients may deteriorate, abandon care they can't afford to self-pay, or simply run out of time.

The American Medical Association surveys document the consequences of prior authorization delays in clinical practice:

• 94% of physicians report that prior authorization delays patient access to necessary care
• 33% report that a patient experienced a serious adverse event as a direct result of a prior authorization delay
• 16% report a patient was hospitalized who would not have been hospitalized without the delay

The documentation request cycle is a refinement of delay. Request one form. Wait for it. When it arrives, request another. Each cycle takes two to four weeks and adds administrative cost to both the patient's side (time, paperwork, physician effort) and the insurer's side — which the insurer can absorb and the patient often cannot. After several cycles, many patients abandon the claim. The insurer never formally denied anything.

For long-term care and disability insurance — products sold specifically to people who anticipate needing sustained support — delay is the core denial mechanism. A disability claimant waiting 18 months for a decision loses their home, spends down their savings, and frequently settles for a fraction of what they are owed. A long-term care claimant who dies during the processing window costs the insurer nothing. The strategic value of delay scales with the severity of the patient's condition. The industry designs for this.

For claims that survive denial-and-delay and become litigation, the industry defends aggressively regardless of merit. The economics favor this. An insurance company's legal department is a fixed cost; the litigation expense of any given case is marginal. For the patient's attorney — typically working contingency or at hourly rates the patient advances — the financial attrition is asymmetric.

The documented bad-faith litigation pattern across the industry includes:

• Missing discovery deadlines as a cost-imposition tactic, forcing opposing counsel to spend time on motions to compel
• Filing motions designed primarily to generate attorney fee expenditure on the opposing side
• Withholding relevant internal documents until courts order production — often years into litigation
• Refusing to depose witnesses the insurer knows would support the patient's claim
• Offering settlement at fractions of acknowledged liability when the patient's cash position becomes exhausted

Settlement under duress is the primary output of the defend stage. Many patients — even those with clearly valid claims, even those who have already won at earlier stages — accept pennies-on-the-dollar resolutions because they cannot sustain the litigation. The insurer does not win these cases in court. It wins them through financial exhaustion.

The Aetna nurse whistleblower case (Hisham Atiyeh) documented a pattern of internal instruction to deny claims without clinical review — and a subsequent internal response when the pattern became legally exposed that prioritized legal defense strategy over patient remediation. Aetna's 2016 case, involving a nurse who alleged that coverage denials were systematically made without reading medical records, resulted in deposition testimony showing the medical director had not reviewed the patient's records before denying the claim. The case settled. The practice was not adjudicated as illegal.

The deposition stage is the final instrument of attrition. If a patient or their surviving family wins at trial — or survives the defend stage with enough remaining resources to reach appellate review — the industry deploys the deposition as a weapon of cost imposition and reputational pressure.

Physicians who testify against insurer denial decisions — as expert witnesses, as treating physicians, or as whistleblowers — are deposed aggressively. The depositions serve multiple functions: they generate legal costs that discourage future testimony, they create documented records that can be used in licensing board proceedings, and they signal to the broader medical community that testifying against insurer decisions carries professional cost. The effect is a chilling of medical expert testimony on behalf of denied patients.

For death cases — claims in which the patient died before the case resolved — the deposition of surviving family members is a documented litigation tactic. Estate of Lokken v. UnitedHealth Group (D. Minn., 2023) documents cases in which elderly patients died after coverage was cut over physician objection, and their families continued litigation. The families can be deposed. Their grief, their memories of their loved one's final months, their financial records — all available to the insurer's legal team as material for attrition.

The word "depose" on Luigi Mangione's bullet casings captured something accurate about this stage: it is the final act in a system designed not to determine justice but to exhaust the capacity to pursue it. The four steps are not independent failures of a process designed to pay claims. They are the process.

The four-step playbook is not the pathology of any single bad actor. It is the optimization function of the US health insurance industry as it is currently structured. Every major insurer deploys versions of every step because every step is profitable in expectation:

• Deny. Denied-and-not-appealed = pure margin. Premium collected, care not paid for.
• Delay. Delayed-and-abandoned = pure margin. Same outcome through exhaustion rather than rejection.
• Defend. Defended-to-settlement = partial liability recovery. The settlement is less than the claim. The difference is profit, minus legal costs that remain below the difference.
• Depose. Deposed-to-attrition = avoided full liability. The chilling effect on future plaintiffs and expert witnesses generates future savings that are not on any balance sheet but are understood by the legal departments who execute the strategy.

The concentration of the US health insurance industry in the decades after 1980 eliminated the competitive pressure that would have forced a more patient-oriented model. Five companies — UnitedHealth Group, Elevance Health (formerly Anthem), Cigna, Humana, and CVS/Aetna — dominate the private insurance market. They do not compete meaningfully on denial rates, on patient outcomes, or on claims payment speed. The markets in which they compete — employer group plans, Medicare Advantage, ACA exchange products — are structured such that patients rarely choose their insurer directly and rarely have meaningful comparative information about denial rates when they do.

The industry's capital allocation confirms the analysis. Combined stock buybacks across the US health insurance industry since 2010 total approximately $120 billion. UnitedHealth Group alone: approximately $54 billion — 44% of the industry total, drawn from premiums paid by 49 million members. That capital was extracted from a business that exists to pay for healthcare. It went to shareholders instead.

UnitedHealthcare's 2023 net income: $16 billion. Denial rate: 32%. Two named plaintiffs in the active class action: dead. Number of executives charged: zero. The math does not require malice. It requires only the absence of accountability.

The four-step playbook is documented in specific cases, with named plaintiffs, internal documents, and deposition testimony. These are not allegations. They are the record:

The Deny/Delay/Defend/Depose playbook is legal. Not merely unprosecuted — actively protected by a suite of federal statutes and court decisions that insulate the insurance industry from the accountability that would otherwise disrupt it.

ERISA preemption (1974). The Employee Retirement Income Security Act preempts state bad-faith insurance claims for the 155 million Americans covered under employer-sponsored plans. This is the structural linchpin. In a normal tort system, a company that wrongfully denies a claim and causes harm is liable for compensatory damages — the harm, plus potentially punitive damages for egregious conduct. Under ERISA, a denied patient can sue only for the benefits owed — not for the harm caused by the denial. If UnitedHealth denies coverage for a surgery, the patient has a cardiac event waiting for care, and the patient dies, ERISA limits recovery to the cost of the surgery. Not the death. Not the suffering. Not the deterrence value. Only the denied benefit. This eliminates the financial penalty for the most harmful denials.

• Pilot Life Insurance Co. v. Dedeaux (1987) — SCOTUS held ERISA preempts state claims for bad-faith insurance practice in employer plans
• Aetna Health Inc. v. Davila (2004) — SCOTUS held ERISA preempts state tort claims even where an HMO's coverage decision directly caused patient harm; only ERISA remedies available
• Pegram v. Herdrich (2000) — SCOTUS shielded HMOs from fiduciary breach claims under ERISA for decisions that mix treatment and coverage

McCarran-Ferguson Act (1945). Federal law exempts the insurance industry from federal antitrust law, delegating regulation to the states. Industry-coordinated practices — including shared algorithmic denial standards, coordinated prior authorization requirements, and industry-wide claim processing protocols — that would constitute antitrust violations in any other sector are legal here. The industry can coordinate; patients cannot.

State insurance commissioners. The regulators who govern insurance at the state level are routinely staffed by former insurance executives and frequently rotate to industry positions after their regulatory service. State regulators rarely impose meaningful penalties for denial-rate outliers; enforcement actions are uncommon and settlements are typically fractions of the harm caused. The insurance lobby is among the most powerful in every state capital.

The legal system is part of the documented problem, not the standard by which to measure whether a harm occurred. This site uses both — documenting the legal record while naming the protections as part of the pattern.

The mortality and morbidity consequences of the Deny/Delay/Defend/Depose playbook are documented in the peer-reviewed literature. These are conservative estimates; the causal chain between insurance denial and patient harm is deliberately obscured by a system that produces no central reporting requirement:

The comparative international record is the clearest evidence of the system's discretionary character. The United States spends 17.1% of GDP on healthcare — more than any comparable nation. Its life expectancy ranks below 50 countries. Its maternal mortality rate is the highest in the developed world. Its medical bankruptcy rate is unique among wealthy nations: other countries with universal coverage systems report essentially zero. The difference is not demographic or genetic. It is structural: other countries pay for healthcare. The US insurance system is optimized to avoid doing so.

The Himmelstein et al. 2019 study — published in the American Journal of Medicine — found that 530,000 bankruptcy filings per year are attributable to medical causes. Most of the affected households had health insurance at the time of illness. The insurance did not protect them. The gap between what was covered and what was owed — produced by denial, prior authorization delays, out-of-pocket maximums, and claim disputes — produced the bankruptcy. This is the documented downstream consequence of the four-step playbook at scale.

Brian Thompson was the CEO of UnitedHealthcare from April 2021 until his killing in Manhattan on December 4, 2024. The alleged shooter, Luigi Mangione, was found with shell casings engraved with three of the four words: "deny," "delay," and "depose." The fourth — "defend" — was inscribed on the silencer.

The cultural recognition that followed was not manufactured outrage. It was accumulated testimony: people who had lost parents to denied post-acute care, people who had spent years appealing denials while their conditions progressed, people who had watched claims processors laugh during recorded calls. The social media outpouring in the days after Thompson's killing documented the breadth of direct, personal harm produced by the system he ran.

An Emerson College poll conducted in December 2024 found that a majority of Americans either supported or expressed empathy with the alleged shooter — not because they endorsed the act, but because the framing it invoked was recognizable. The four words named something the public had experienced and had no other political vocabulary for.

The industry's response confirmed the editorial framing.

In the weeks immediately following Thompson's killing, UnitedHealthcare temporarily reduced its claim denial rate. The reduction was measurable — reported across provider networks and tracked by analysts. It lasted through early Q1 2025 before denial rates reverted toward the prior baseline as public attention faded. The reversion is the admission: the denial regime was discretionary. They could always have approved more claims. They chose not to. The temporary reduction proved the prior rate was not actuarially required.

Simultaneously, executives at UnitedHealth Group, Elevance Health (Anthem), Cigna, CVS/Aetna, and Humana removed leadership biographies and executive photos from their public websites. The industry's leadership had not hidden itself from regulators, from shareholders, from journalists who had been writing about denial rates for years. They hid from the public. The Wayback Machine documents the before and after.

The hiding is not an admission of legal guilt. It is evidence that the executives recognized what the public had recognized: that the systemic violence their companies inflict had become legible as violence, and that they personally bore individual responsibility for it. They were not afraid of one alleged shooter. They were afraid of being named by a public that had stopped viewing them as anonymous administrators of routine corporate processes.

The political response followed the pattern documented throughout this site. Senate hearings were held. UnitedHealth CEO Andrew Witty testified. No legislation passed. Denial rates returned to baseline. The four companies that dominate the market reported their earnings. The story moved on.

The Thompson moment is a node in a longer arc. The arc began in 1945 with McCarran-Ferguson. It runs through ERISA (1974), Pilot Life (1987),Davila (2004), and naviHealth ($2.5B, 2020). It runs through Gene Lokken and Dale Tetzloff. It runs through 530,000 medical bankruptcies per year. The four words named the arc. The thread you are reading documents it.

The Deny/Delay/Defend/Depose playbook exists because it is legal, profitable, and structurally protected. Ending it requires changing at least one of those conditions. The available paths:

Single-payer / Medicare for All. A universal coverage system eliminates the private insurance apparatus entirely. The DDDD playbook depends on private insurers making coverage decisions driven by profit motive. A publicly-administered single-payer system — structured like Medicare for all rather than Medicare Advantage, which reintroduces the insurer incentive structure — eliminates the profit motive from coverage decisions. This is the only structural solution. Every incremental reform leaves the apparatus intact. The political obstacles are not technical. The insurance industry and its allied employers' associations spent hundreds of millions of dollars in the 2009–2010 healthcare debate to prevent even a public option from reaching a floor vote. The ACA's individual mandate generated $54 billion in annual revenue for private insurers. The industry is not fighting to preserve a market; it is fighting to preserve an extraction apparatus.

Strict regulatory enforcement. Denial-rate caps — requiring insurers to approve at least X% of in-network claims — would constrain the most egregious denial engines. Automatic approval after X days of prior authorization review would eliminate delay as a strategy. Mandatory denial-rate transparency — public disclosure, by insurer and plan, of denial rates, appeal rates, and appeal reversal rates — would create competitive pressure. All three have been proposed in various legislative sessions. All three have been killed by industry lobbying before reaching a vote.

ERISA reform. Restoring state bad-faith tort liability for employer-sponsored plans would change the financial calculus immediately. If the harm caused by wrongful denial were compensable at the scale of the harm — not merely the benefit denied — the denial rate would fall. This requires Congressional action; the preemption is statutory, not constitutional. The last serious ERISA bad-faith reform proposal was the Patients' Bill of Rights debate in 1999–2001. It was killed in conference.

Mass-tort class action breakthroughs. The Lokken class action — if it survives UnitedHealth's continuing motions and reaches a damages phase — could create legal precedent that recalibrates the financial calculus for algorithmic denial. The class is estimated in the hundreds of thousands of Medicare Advantage patients. Damages at ERISA's constrained recovery standard may still be significant at that scale. A damages verdict that exceeded the cost savings from the denial program would be the first time the math stopped working in favor of the playbook.